吸入布地奈德治疗过敏性肺泡炎的临床应用研究  

Clinical observation of the Pulmicort on sequoiosis by inhaling

作　　者：唐颖[1] 许力军[1] 于振香[1] 李洋[1] 熊桂兰[1] 孙安凤[1] 李晓丹[1] 

机构地区：[1]吉林大学第一临床医学院呼吸科,吉林长春130021

出　　处：《中国现代医学杂志》2008年第17期2531-2533,共3页China Journal of Modern Medicine

摘　　要：目的通过临床分析布地奈德混悬液(普米克令舒)雾化吸入治疗过敏性肺泡炎的疗效。方法将18名过敏性肺泡炎患者随机分成两组。对照组8例采用抗生素、氨茶碱、静脉激素常规治疗,治疗组10例采用抗生素、氨茶碱、局部吸入激素治疗。观察两组患者临床症状、体征缓解时间,并对治疗前后嗜酸性粒细胞计数及肺功能进行比较。结果观察组和对照组在疗效上差异有显著性(P<0.05),观察组在缓解临床症状、体征、改善肺功能及改善血嗜酸性粒细胞计数上优于对照组(P<0.05)。结论雾化吸入普米克令舒治疗过敏性肺泡炎可快速缓解患者症状,改善肺功能,缩短病程,且不良反应少,患者容易耐受。[Objective] To investigate the clinical effects of Budesonide （Pulmicort） on sequoiosis by inhaling. [Methods] eigheteen patients with sequoiosis are randomly divided into two groups：eight patients as control group, ten patients as experimental group. The control group were treated with antibiotics, Aminofdina and hormone by vein. While the experimental group were treated with antibiotics, Aminofilina and Pulmicort by inhaling. The clinical symptom, the lasting time of physical sign of the two gourps were observed.And the changes of the value of EOS and VC were compared before and after the treatment. [Results] There is significant difference between the controi group and the experimental group （P 〈0.05）. The experimental group is superior to the control group on the time of alleviating clinical symptom and physical sign, and on the improvement of pulmonary function and the value of EOS. [Conclusion] Inhaling the Pulmicort can rapidly alleviate the clinical symptoms, improve the pulmonary function and shorten the course of disease of the sequoiosis patients. And this therapy has little adverse reaction, so the patients can easily tolerant.

关 键 词：过敏性肺泡炎 雾化吸入 普米克令舒 

分 类 号：R563.1[医药卫生—呼吸系统]